GeoVax Shares Surge After Cancer Vaccine Patent In US

  • GeoVax Labs Inc GOVX has received a U.S. patent covering its vector platform for expressing tumor-associated antigens in virus-like particles (VLPs).
  • The platform comes from a Modified Vaccinia Ankara (MVA) viral vector and encompasses GeoVax's Mucin 1 (MUC1) tumor-associated antigen immunotherapy candidate.
  • GeoVax's initial results with its MVA-VLP-MUC1 immunotherapy candidates have been encouraging.
  • David Dodd, GeoVax President, and CEO commented, "This patent allowance adds to our growing portfolio of wholly-owned, co-owned, and in-licensed intellectual property, which now stands at over 70 granted or pending patent applications spread over 20 patent families."
  • Related Link: GeoVax Labs In-Licenses Development Rights To Multi-Antigenic COVID-19 Vaccine Candidate.
  • Price Action: GOVX shares are 19.70% at $4.62 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsPatentswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!